Trials / Completed
CompletedNCT00395577
A Study in Rheumatoid Arthritis With an Investigational Oral p38 MAP Kinase Inhibitor VX-702
A Phase 2, 12-Week, Randomized, Placebo-Controlled Study to Evaluate the Antiinflammatory Effects of VX-702 When Administered Concomitantly With Methotrexate
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 120 (planned)
- Sponsor
- Vertex Pharmaceuticals Incorporated · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to assess the safety and effects of VX-702 in subjects with moderate to severe rheumatoid arthritis and who are taking the drug methotrexate.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | VX-702 |
Timeline
- Start date
- 2006-11-01
- Completion
- 2007-07-01
- First posted
- 2006-11-03
- Last updated
- 2007-12-07
Locations
17 sites across 6 countries: Bulgaria, Croatia, Poland, Russia, Serbia and Montenegro, Slovenia
Source: ClinicalTrials.gov record NCT00395577. Inclusion in this directory is not an endorsement.